ERBB2 and breast cancer: In HER2+ BC, the oncogenetic activation of the membrane thyrosine kinase HER2 promotes pathogenesis and the progression of cancer cells by interacting with the PI3K/AKT/mTOR pathway and other signaling pathways [19].